Choose One, Not Both: Why Balanced Biopharma Funds Stumble
This article was originally published in Start Up
By the end of this year, three major US venture firms---JP Morgan Partners, the American affiliate of Apax, and MPM Capital--will be transformed. Their partners are leaving; their strategies are changing. And their stories are all marked by their common failure to combine early-stage biopharmaceutical venture capital with later-stay growth capital and buyouts into so-called "balanced funds."
You may also be interested in...
Clarus Ventures, a year-and-a-half removed from raising its debut fund, likely will return for seconds later this year, and the firm is betting its new strategy for investing in medical device companies promises to produce returns that its limited partners will enjoy.
Europe's investment environment has forced much of the biotech sector to morph into specialty pharma. The situation isn't likely to change fast. Executives had best adapt, rather than complain.
In dermatology offshoot Intendis, Schering AG has created the ideal European crossbreed: a group with the management experience associated with spin-outs, and a revenue-generating side more typical of specialty pharma. The snag: Schering's retaining full ownership--for now.